Assessment of Steatosis and Fibrosis in Liver Transplant Recipients Using Controlled Attenuation Parameter and Liver Stiffness Measurements

Table 3

Univariate and multivariate analysis of predictors of steatosis (elevated CAP ≥238 dB).

Variables	Univariate		Multivariate
	OR (95% CI)	value	OR (95% CI)	value
Age at LT, years	1.04 (1.01–1.07)	0.026	0.94 (0.91–1.09)	0.445
Age at TE, years	1.04 (1.01–1.07)	0.008	1.05 (0.90–1.22)	0.494
Donor age, years	0.99 (0.97–1.01)	0.462
Gender (female ref.)	2.78 (1.42–5.46)	0.003	2.73 (1.25–5.94)	0.011
Cause of liver disease
Autoimmune liver disease	0.29 (0.11–0.76)	0.012	0.50 (0.16–1.57)	0.239
Alcoholic liver disease	2.74 (1.26–5.96)	0.011	1.61 (0.67–4.03)	0.277
Others	0.61 (0.32–1.17)	0.134
BMI, kg/m^2	1.03 (0.94–1.13)	0.509
Donors BMI, kg/m^2	1.01 (0.93–1.10)	0.867
Hypertension	2.08 (1.07–3.99)	0.031	1.23 (0.52–2.90)	0.631
Diabetes	2.67 (1.03–4.15)	0.040	0.85 (0.32–2.23)	0.749
Thrombocytes x10^9/L	1.01 (0.99–1.02)	0.545
Glucose, mmol/L	1.37 (1.06–1.78)	0.017	1.07 (0.81–1.42)	0.605
Total bilirubin, mmol/L	1.98 (0.95–1.01)	0.206
ALT, U/L	1.01 (0.99–1.02)	0.592
AST, U/L	1.01 (0.99–1.02)	0.385
GGT, U/L	1.01 (0.99–1.02)	0.332
Triglyceride, mmol/L	2.67 (1.46–4.90)	0.002	1.19 (0.16–8.54)	0.862
Total cholesterol, mmol/L	1.47 (1.07–2.02)	0.018	7.46 (1.78–31.15)	0.006
LDL, mmol/L	1.61 (1.10–2.35)	0.015	1.21 (0.91–1.46)	0.065
HDL, mmol/L	0.39 (0.17–0.91)	0.023	0.09 (0.02–0.42)	0.002
CRP, mg/L	0.99 (0.96–1.01)	0.305
LSM, kPa	1.03 (0.97–1.09)	0.287
Time from LT to TE, years	1.14 (0.99–1.30)	0.065

LT, liver transplantation; NAFLD, nonalcoholic fatty liver disease; HCV, hepatitis C virus infection; BMI, body mass index; AST, serum aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; CRP, C-reactive protein; LSM, liver stiffness measurement; TE, transient elastography.